J R Fraser Cummings

List of Publications by Year
in descending order

77	6,189	185998 28	128067 60
papers	citations	h-index	g-index

78	78	78	7959
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. Expert Opinion on Biological Therapy, 2022, 22, 203-223.	1.4	8
2	Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study. Frontline Gastroenterology, 2022, 13, 477-483.	0.9	2
3	Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]. Journal of Crohn's and Colitis, 2022, 16, 911-921.	0.6	21
4	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs, 2021, 13, 1868078.	2.6	17
5	Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK. BMJ Open Gastroenterology, 2021, 8, e000530.	1.1	6
6	Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease. Inflammatory Bowel Diseases, 2021, 27, 1641-1652.	0.9	62
7	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	6.1	233
8	JAK1 inhibition and inflammatory bowel disease. Rheumatology, 2021, 60, ii45-ii51.	0.9	27
9	Early real-world effectiveness of ustekinumab for Crohnâ€™s disease. Frontline Gastroenterology, 2020, 11, 111-116.	0.9	28
10	MicroRNA23a Overexpression in Crohnâ€™s Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier. Journal of Crohn's and Colitis, 2020, 14, 381-392.	0.6	8
11	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohnâ€™s Disease. Gastroenterology, 2020, 158, 189-199.	0.6	249
12	High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. BMJ Open Gastroenterology, 2020, 7, e000532.	1.1	10
13	Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. Frontline Gastroenterology, 2020, 11, 178-187.	0.9	59
14	Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. Journal of Crohn's and Colitis, 2020, 14, 1653-1661.	0.6	9
15	Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Digestive and Liver Disease, 2020, 52, 1259-1265.	0.4	7
16	Life in lockdown: experiences of patients with IBD during COVID-19. BMJ Open Gastroenterology, 2020, 7, e000541.	1.1	32
17	Anti-TNF biosimilars in Crohnâ€™s Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology and Hepatology, 2019, 13, 731-738.	1.4	16
18	Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005â€“2013. Alimentary Pharmacology and Therapeutics, 2019, 50, 176-192.	1.9	15

#	Article	IF	Citations
19	Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. BioDrugs, 2019, 33, 241-253.	2.2	34
20	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	3.7	431
21	A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK. Medicine (United States), 2019, 98, e14681.	0.4	5
22	A Novel Alternative to Colectomy for Severe Intractable Constipation in Adults: How to Avoid Surgery in Severe Cases?. Archives of Clinical and Medical Case Reports, 2019, 03, .	0.0	0
23	The monitoring and incidence of hyperglycaemia in inflammatory bowel disease patients treated with intravenous steroids. Clinical Medicine, 2019, 19, s20-s20.	0.8	0
24	Review article: treatingâ€toâ€target for inflammatory bowel diseaseâ€associated anaemia. Alimentary Pharmacology and Therapeutics, 2018, 48, 610-617.	1.9	28
25	MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor Î±-1. Genes, 2018, 9, 85.	1.0	49
26	MicroRNA-31 Targets Thymic Stromal Lymphopoietin in Mucosal Infiltrated CD4+ T Cells: A Role in Achieving Mucosal Healing in Ulcerative Colitis?. Inflammatory Bowel Diseases, 2018, 24, 2377-2385.	0.9	12
27	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapyâ€"Access to Rapid Treatment (iSTART) approach. Intestinal Research, 2018, 16, 522-528.	1.0	17
28	Inflammatory bowel disease registries for collection of patient iron parameters in Europe. World Journal of Gastroenterology, 2018, 24, 1063-1071.	1.4	4
29	Editorial: CTâ€P13, a biosimilar of antiâ€tumour necrosis factorâ€alpha agent (infliximab), in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 45, 1370-1371.	1.9	1
30	Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. Journal of Crohn's and Colitis, 2017, 11, jjw216.	0.6	118
31	Transcriptomic Profiling of Intestinal Macrophages Isolated from Patients Reveals a Profound Gene Expression Reprogramming Underlying IBD Pathogenesis. Gastroenterology, 2017, 152, S612.	0.6	0
32	Roundtable on registries: practical considerations for registries â€" making them work, London, UK, 26 January 2017. GaBI Journal, 2017, 6, 122-134.	0.4	1
33	The impact of an inflammatory bowel disease nurse-led biologics service. Frontline Gastroenterology, 2016, 7, 283-288.	0.9	8
34	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 273-282.	3.7	91
35	Sa1830 microRNA23a Is Overexpressed in the Colonic Epithelium in Crohn's Disease. Gastroenterology, 2016, 150, S375.	0.6	0
36	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	0.6	85

#	Article	IF	Citations
37	MicroRNAs in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2015, 21, 1160-1165.	0.9	18
38	Mo1728 Cytokine and microRNA Expression in Colonic and Ileal Crohn's Disease Is Modified by Drug Therapy in an Ex Vivo Model. Gastroenterology, 2015, 148, S-695-S-696.	0.6	0
39	Mo1727 Drug Therapies in Ulcerative Colitis Influence the Expression of MicroRNAs and Cytokines in the Sigmoid Mucosa in an Ex Vivo Model. Gastroenterology, 2015, 148, S-695.	0.6	0
40	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology and Therapeutics, 2014, 40, 1313-1323.	1.9	55
41	HLA-DQA1â€“HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	9.4	165
42	Tuberculosis and TNF-inhibitors: history of exposure should outweigh investigations. BMJ Case Reports, 2014, 2014, bcr2013202127-bcr2013202127.	0.2	5
43	Sa1196 Prospective, Randomized, Double-Blind, Sham-Treatment Controlled Multi-Center Study to Evaluate Efficacy and Safety of Leukocytapheresis (LCAP) Using ACD-A As Anticoagulant in Patients With Steroid-Free, Active Ulcerative Colitis. Gastroenterology, 2013, 144, S-226.	0.6	1
44	Su1228 Thiopurine Withdrawal for Sustained Remission in IBD: A UK Multicentre Study. Gastroenterology, 2013, 144, S-433-S-434.	0.6	1
45	Improving outpatient services: the Southampton IBD virtual clinic. Postgraduate Medical Journal, 2012, 88, 487-491.	0.9	32
46	Improving outpatient services: the Southampton IBD virtual clinic. Frontline Gastroenterology, 2012, 3, 76-80.	0.9	18
47	Tu1925 MicroRNA Expression in Treatment Naive Active and Inactive Ulcerative Colitis. Gastroenterology, 2012, 142, S-879.	0.6	0
48	Sa1923 The Role of Histone Deacetylase Inhibition in Ex Vivo and In Vitro Models of Inflammatory Bowel Diseases. Gastroenterology, 2012, 142, S-360.	0.6	0
49	A man with bloody diarrhoea. BMJ: British Medical Journal, 2012, 344, e978-e978.	2.4	0
50	Nutrition and inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 491-496.	1.3	18
51	Association of caspaseâ€9 and RUNX3 with inflammatory bowel disease. Tissue Antigens, 2011, 77, 23-29.	1.0	14
52	Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis. Journal of Immunology, 2011, 186, 2672-2680.	0.4	260
53	The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens, 2010, 76, 48-56.	1.0	56
54	The pattern and outcome of acute severe colitis. Journal of Crohn's and Colitis, 2010, 4, 431-437.	0.6	276

#	Article	IF	Citations
55	Association between genetic variants in myosin IXB and CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1014-1021.	0.9	25
56	S1132 Neoplasia Within 10 Years of Diagnosis of Ulcerative Colitis. Gastroenterology, 2009, 136, A-196.	0.6	0
57	S1142 The Pattern and Outcome of Acute Severe Colitis. Gastroenterology, 2009, 136, A-199.	0.6	0
58	Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2008, 14, 500-507.	0.9	24
59	Clinical and molecular characteristics of isolated colonic CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2008, 14, 1667-1677.	0.9	38
60	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics, 2008, 40, 710-712.	9.4	403
61	298 The Genetics of Nod-like Receptor Proteins in Crohn's Disease. Gastroenterology, 2008, 134, A-42.	0.6	0
62	W1257 The Arg381gln SNP in IL 23 R Does Not Influence Response to Immunomodulators in Ulcerative Colitis or Crohn's Disease. Gastroenterology, 2008, 134, A-666.	0.6	0
63	W1258 The Combined Effect of the Aicartase C347g and the Aldehyde Oxidase A3505g SNPs Predict Efficacy of Methotrexate Therapy in Inflammatory Bowel Disease. Gastroenterology, 2008, 134, A-666.	0.6	0
64	W1847 Prevalence and Determinants of PSC in a Cohort of Patients with Inflammatory Bowel Disease and Normal Liver Function Tests. Gastroenterology, 2008, 134, A-837.	0.6	0
65	Medical management of Crohnâ€™s disease. BMJ: British Medical Journal, 2008, 336, 1062-1066.	2.4	52
66	IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease. Gastroenterology, 2007, 132, 1657-1664.	0.6	170
67	Confirmation of the role of ATG16l1 as a CrohnÊ¼s disease susceptibility gene. Inflammatory Bowel Diseases, 2007, 13, 941-946.	0.9	98
68	Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflammatory Bowel Diseases, 2007, 13, 1063-1068.	0.9	81
69	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	9.4	1,298
70	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics, 2007, 39, 830-832.	9.4	1,063
71	Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes and Immunity, 2006, 7, 576-582.	2.2	58
72	Oral methotrexate in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2005, 21, 385-389.	1.9	75

#	Article	IF	Citations
73	Clinical Implications of Inflammatory Bowel Disease Genetics on Phenotype. Inflammatory Bowel Diseases, 2005, 11, 56-61.	0.9	23
74	QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study. BMJ: British Medical Journal, 1998, 316, 745-746.	2.4	122
75	Hypopituitarism following Coronary Artery Bypass Surgery. Scottish Medical Journal, 1997, 42, 116-117.	0.7	6
76	The effects of an integrated education programme on the management of diabetic ketoacidosis. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1995, 12, 235-237.	0.2	0
77	Abnormal Insulin Treatment Behaviour: a Major Cause of Ketoacidosis in the Young Adult. Diabetic Medicine, 1995, 12, 429-432.	1.2	41